Pre-made Felvizumab benchmark antibody (Whole mAb, anti-RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] therapeutic antibody (Pre-made Felvizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus.[1][2]
| Products Name (INN Index) | Pre-Made Felvizumab Biosimilar, Whole Mab: Anti-Rsv (Respiratory Syncytial Virus) Glycoprotein F [Respiratory Syncytial Virus] therapeutic antibody |
|---|---|
| INN Name | felvizumab |
| Target | RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Centocor?Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] |
| Package |
